Adjusting Statin Doses to a Cholesterol Goal Versus Fixed Doses in Heart Disease
Compares adjusting statin doses to a cholesterol goal with fixed doses in heart disease.
Plain-language title generated from the registry record
Registry title: Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease
Key facts
- Where
- Peshawar, PakistanSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07909915, who can take part
Where in Pakistan
- Rehman Medical InstitutePeshawar, PakistanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rehman Medical Institute - RMI
- Trial code
- NCT07909915
- Record updated
- 5 November 2026
- Original description
To compare the efficacy of fixed-dose versus treat-to-target statin regimens in achieving the predefined LDL-C target at 12 weeks in patients with established ASCVD.Read full original descriptionShow less
Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease: A Randomized Controlled Trial
To compare the efficacy of fixed-dose versus treat-to-target statin regimens in achieving the predefined LDL-C target at 12 weeks in patients with established ASCVD.
To compare the frequency of adverse effects of statin therapy between patients receiving a fixed-dose regimen and those managed with a treat-to-target approach.
Inclusion: adults aged between 18 to 80 years requiring primary prevention or those with history of at least 1 episode of ASCVD; who are either statin-naïve or already on statins but not at target LDL-C levels and are eligible for dose adjustment.
Exclusion: have known hypersensitivity or a prior life-threatening reaction to any statin; are using other lipid-lowering agents like ezetimibe, PCSK9 inhibitors, fibrates, or bile acid sequestrants; have contraindications to statin therapy such as active liver disease or severe renal impairment (eGFR < 30 mL/min/1.73m²); have already achieved target LDL-C levels on a high-dose statin and tolerate it well; are pregnant or lactating.